FDA Decisions Expected: October 2025 Prime Therapeutics Portal The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Best BPC 157 Oral Supplements: ProHealth's Triple Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026 In 2023, the FDA deemed 19 peptides too unsafe to be dispensed by compounding pharmacies. Now, under RFK Jr., the agency is poised to reverse itself despite the fact that few Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review